Contineum Therapeutics (CTNM) Common Equity (2023 - 2026)

Contineum Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $250.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 35.33% year-over-year to $250.0 million; the TTM figure through Mar 2026 stood at $250.0 million (up 35.33% YoY), while the FY2025 annual figure was $261.0 million, up 31.77% from the prior year.
• Common Equity was $250.0 million for Q1 2026 at Contineum Therapeutics, down from $261.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $261.0 million in Q4 2025 to a low of -$97.5 million in Q1 2023.
• Historically, Common Equity has averaged $101.2 million across 4 years, with a median of $180.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 492.38% in 2024, then fell 21.2% in 2025.
• A 4-year view of Common Equity shows it stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then jumped by 31.77% to $261.0 million in 2025, then fell by 4.19% to $250.0 million in 2026.
• The last three Common Equity figures came in at $250.0 million (Q1 2026), $261.0 million (Q4 2025), and $180.5 million (Q3 2025), per Business Quant data.